GHRP-2
General information:
Manufacturer: Generic
: 95% GH rleasing peptide
2
Pack: kit 10 vials x 5 mg/vial
GHRP-2 is a true hGH secretagogue. Which means it stimulates the
body's own secretion of hGH as explained in the study below. Human
Growth hormone has been shown in studies to promote lean body mass and
reduce adiposity (fat).
"The group compared ITT to stimulation with GH releasing peptide 2
(GHRP-2). The synthetic hexapeptide, also named pralmorelin, is derived
from a metenkephalin peptide. It is the most potent of the family of
synthetic GH stimuli known in humans and acts via the endogenous
ghrelin receptor (12). As these receptors have been identified both in
the hypothalamus and the pituitary, GHRP-2 action may not be restricted
to the pituitary. Previous data confirmed by the recent work of Chihara
et al. in the present issue suggest a dose-dependent and specific GH
release in healthy volunteers independent of age, sex and obesity (13),
and support the results of the combination tests of GHRP-2 with GHRH
(14)."
GHRP ? 2 also has a protective effect on the liver and an
anti-inflammatory effect. These are paramount attributes for
experiments involving muscle synthesis and recovery.
"It has been reported that growth hormone (GH)-releasing peptide-2
(GHRP-2), a ghrelin receptor agonist, has an anti-inflammatory effect.
We investigated whether this GH secretagogue attenuates liver injury in
LPS-treated rats. Wistar rats were simultaneously injected (ip) with
LPS (1 mg/kg) and/or GHRP-2 (100 microg/kg). Serum levels of aspartate
and alanine transaminases were measured as an index of liver damage.
Circulating nitrites/nitrates and hepatic IGF-I and TNF-alpha were
evaluated as possible mediators of GHRP-2 actions. LPS increased serum
levels of transaminases and nitrites/nitrates. Moreover, LPS increased
hepatic TNF-alpha and decreased hepatic IGF-I mRNAs. GHRP-2
administration attenuated the effects of LPS on transaminases,
nitrites/nitrates, TNF-alpha, and IGF-I in vivo. This GHRP-2 effect
does not seem to be due to modifications in food intake, since fasting
did not modify serum levels of transaminases, serum nitrites/nitrates,
and hepatic TNF-alpha mRNA both in vehicle rats and in LPS-injected
rats. To elucidate whether GHRP-2 is acting directly on the liver,
cocultures of hepatocytes and nonparenchymal cells and monocultures of
isolated hepatocytes were incubated with LPS and GHRP-2. The ghrelin
receptor agonist prevented an endotoxin-induced increase in
transaminases and nitrite/nitrate release as well as in TNF-alpha mRNA
and increased IGF-I mRNA from cocultures of hepatocytes and
nonparenchymal cells, but not from monocultures. In summary, these data
indicate that GHRP-2 has a protective effect on the liver in
LPS-injected rats that seems to be mediated by IGF-I, TNF-alpha, and
nitric oxide. Our data also suggest that the anti-inflammatory effect
of GHRP-2 in the liver is exerted on nonparenchymal cells."
GHRP 2 has demonstrated that it is very effective at stimulating
GH production in test subjects. It has a short half life with peak
concentrations occurring around 15 minutes and not longer than 60
minutes after administration.